Baker Bros Advisors LP Has Lowered Position in Chemocentryx (CCXI) as Shares Rose; As Owens Corning New (OC) Market Valuation Declined, Lodge Hill Capital Has Lowered Stake

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Baker Bros Advisors Lp decreased its stake in Chemocentryx Inc. (CCXI) by 50% based on its latest 2018Q4 regulatory filing with the SEC. Baker Bros Advisors Lp sold 207,000 shares as the company’s stock rose 6.99% with the market. The hedge fund held 207,029 shares of the health care company at the end of 2018Q4, valued at $2.26M, down from 414,029 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Chemocentryx Inc. for a number of months, seems to be less bullish one the $721.54 million market cap company. The stock decreased 0.72% or $0.09 during the last trading session, reaching $12.43. About 226,159 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since May 19, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Lodge Hill Capital Llc decreased its stake in Owens Corning New (OC) by 2.47% based on its latest 2018Q4 regulatory filing with the SEC. Lodge Hill Capital Llc sold 13,305 shares as the company’s stock declined 3.74% while stock markets rallied. The hedge fund held 525,095 shares of the industrial machinery and components company at the end of 2018Q4, valued at $23.09 million, down from 538,400 at the end of the previous reported quarter. Lodge Hill Capital Llc who had been investing in Owens Corning New for a number of months, seems to be less bullish one the $5.26B market cap company. The stock decreased 1.56% or $0.77 during the last trading session, reaching $48.48. About 992,075 shares traded. Owens Corning (NYSE:OC) has declined 36.08% since May 19, 2018 and is downtrending. It has underperformed by 40.45% the S&P500. Some Historical OC News: 17/05/2018 – Terrell Owens goes for Jason Garrett’s head; 04/05/2018 – OWENS CORNING – CREDIT AGREEMENT PROVIDES FOR A REVOLVING CREDIT FACILITY IN AN AGGREGATE PRINCIPAL AMOUNT OF $800 MLN; 25/04/2018 – OWENS CORNING – EXPECTS AN ENVIRONMENT IN 2018 CONSISTENT WITH CONSENSUS EXPECTATIONS FOR U.S. HOUSING STARTS AND GLOBAL INDUSTRIAL PRODUCTION GROWTH; 24/03/2018 – Texas Emissions: 280919 – OWENS CORNING ROOFING AND ASPHALT IRVING FACILITY; 06/03/2018 Azuqua Names Todd Owens CEO and Expands Leadership Team to Drive Next Wave of Growth; 05/04/2018 – Texas Emissions: 281570 – OWENS CORNING ROOFING AND ASPHALT IRVING FACILITY; 25/04/2018 – Owens Corning 1Q Adj EPS 80c; 22/03/2018 – Texas Emissions: 280838 – OWENS CORNING INSULATING SYSTEMS WAXAHACHIE PLANT; 30/03/2018 – OWENS CORNING ARNAUD GENIS RETIRES AS PRESIDENT, COMPOSITES; 08/03/2018 – Rep. LaHood: Senate Passes LaHood Bill to Honor Fallen Navy SEAL Ryan Owens

Investors sentiment increased to 0.92 in Q4 2018. Its up 0.31, from 0.61 in 2018Q3. It increased, as 51 investors sold OC shares while 97 reduced holdings. 55 funds opened positions while 81 raised stakes. 99.45 million shares or 1.03% less from 100.48 million shares in 2018Q3 were reported. Natl Bank Of America De holds 0.01% or 1.39M shares. Buckingham Mgmt holds 0.82% or 124,000 shares. Bnp Paribas Arbitrage Sa holds 0% or 862,613 shares. State Street accumulated 2.92 million shares or 0.01% of the stock. Pillar Pacific Capital Management Limited has 0.23% invested in Owens Corning (NYSE:OC) for 39,785 shares. Rock Point Advsr Ltd Liability Corp invested 2.52% of its portfolio in Owens Corning (NYSE:OC). Geode Mngmt Llc has 1.14 million shares. Bain Capital Pub Equity Mngmt Ltd Co holds 0.27% or 65,554 shares in its portfolio. Beaconlight Capital Ltd holds 23,552 shares or 0.36% of its portfolio. Old National Bank In, a Indiana-based fund reported 5,871 shares. 26,490 are owned by Levin Cap Strategies Lp. Dekabank Deutsche Girozentrale stated it has 173,935 shares. Putnam Investments Limited Com holds 0% or 35,360 shares in its portfolio. Cipher Capital LP has 9,121 shares. Bridgewater Associate Lp reported 39,302 shares.

Lodge Hill Capital Llc, which manages about $208.28M and $361.49M US Long portfolio, upped its stake in Cott Corp Que (NYSE:COT) by 63,008 shares to 373,008 shares, valued at $5.20M in 2018Q4, according to the filing. It also increased its holding in Compass Minerals Intl Inc (NYSE:CMP) by 211,200 shares in the quarter, for a total of 236,200 shares, and has risen its stake in United Rentals Inc (NYSE:URI).

Analysts await Owens Corning (NYSE:OC) to report earnings on July, 24. They expect $1.16 earnings per share, down 0.85% or $0.01 from last year’s $1.17 per share. OC’s profit will be $125.93 million for 10.45 P/E if the $1.16 EPS becomes a reality. After $0.54 actual earnings per share reported by Owens Corning for the previous quarter, Wall Street now forecasts 114.81% EPS growth.

More notable recent Owens Corning (NYSE:OC) news were published by: Businesswire.com which released: “Owens Corning Earns No. 1 Ranking on Corporate Responsibility Magazine’s 100 Best Corporate Citizens List – Business Wire” on May 15, 2019, also Seekingalpha.com with their article: “Owens Corning 2019 Q1 – Results – Earnings Call Slides – Seeking Alpha” published on April 24, 2019, Benzinga.com published: “Earnings Scheduled For April 24, 2019 – Benzinga” on April 24, 2019. More interesting news about Owens Corning (NYSE:OC) were released by: Benzinga.com and their article: “Trade War Fears Trigger Nomura Instinet’s Downgrade Of Housing Stocks – Benzinga” published on May 16, 2019 as well as Finance.Yahoo.com‘s news article titled: “Were Hedge Funds Right About Piling Into Owens Corning (OC)? – Yahoo Finance” with publication date: April 23, 2019.

Baker Bros Advisors Lp, which manages about $8.20 billion and $12.21B US Long portfolio, upped its stake in Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) by 11.27M shares to 39.71 million shares, valued at $642.17M in 2018Q4, according to the filing. It also increased its holding in Clementia Pharmaceuticals Inc. by 1.79M shares in the quarter, for a total of 3.72M shares, and has risen its stake in Ra Pharmaceuticals Inc..

More important recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates – Nasdaq” on May 06, 2019, also Nasdaq.com published article titled: “ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019 – Nasdaq”, Seekingalpha.com published: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on May 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) was released by: Globenewswire.com and their article: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” with publication date: May 06, 2019.

Since January 7, 2019, it had 0 insider buys, and 5 insider sales for $1.38 million activity. $158,790 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Cappel Markus J. on Monday, January 7. Shares for $457,747 were sold by KANAYA SUSAN M.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.26 EPS, down 85.71% or $0.12 from last year’s $-0.14 per share. After $-0.23 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 13.04% negative EPS growth.

Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It fall, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Barclays Public Limited Com has 5,866 shares for 0% of their portfolio. Matarin Mgmt Lc reported 0% stake. State Of Wisconsin Invest Board accumulated 23,200 shares. One Trading LP accumulated 13,165 shares or 0% of the stock. Aqr Cap Mgmt Ltd Llc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Nantahala Mgmt Ltd Liability Corp holds 0.21% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 623,338 shares. Bb&T Securities stated it has 114,827 shares. Sei Invs Comm has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Prelude Capital Mngmt Lc invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ptnrs Limited Com reported 19,469 shares. Fernwood Limited Liability Co accumulated 10,000 shares. J Goldman Company LP reported 0.04% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Voya Inv Ltd Liability reported 10,588 shares stake. 2.73 million are held by Blackrock. Panagora Asset Mngmt invested in 324,223 shares.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Depression in Hidradenitis Suppurativa – Senthilnathan – – British Journal of Dermatology

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston‐Salem, North Carolina

Department of Pathology, Wake Forest School of Medicine, Winston‐Salem, North Carolina

Department of Public Health Sciences, Wake Forest School of Medicine, Winston‐Salem, North Carolina

Search for more papers by this author

Source link

In Response: Overall and Subgroup Prevalence of Acne Vulgaris Among Patients with Hidradenitis …

Facial Hidradenitis Suppurativa: A Potential Mimicker of Acne Vulgaris. Noureddine Litaiem, Asma Raboudi, Faten Zeglaoui.

Source link

OM1 Expands Rheumatology Conditions With Specialized Data For Licensing And Advanced Analytics

BOSTON: OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics.
The registries include

Rheumatoid Arthritis
Systemic Lupus Erythematosus
Sjogrens
Giant Cell Arteritis
Systemic Scleroderma
Juvenile Idiopathic Arthritis
Ankylosing Spondylitis
Hidradenitis Suppurativa

The OM1 registries are continually enrolling and updating and include patient reported outcomes as well as linkage to other data sources. These specialized clinical databases are used for streamlining research, understanding treatments and improving patient outcomes for life sciences companies and providers.

Understanding these conditions at a deeper level is critical to every stakeholder. We are proud to be advancing research and improving care through better, more complete and timely data, said Dr. Richard Gliklich, CEO of OM1. Enabling our customers to have direct access to research-grade data will help advance care even more rapidly.

The registry data is available for licensing and through OM1’s advanced data visualization and analytics tools. For more information, visit www.om1.com.

Source link

About the Market Strategies, Adopted by Leading Respective Organizations 2024 – The AZK News

Humira

Humira Market report presents a complete overview, market shares, and growth opportunities of market, by product type, application, key manufacturers and key regions and countries. The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

Get Sample PDF Copy of Humira Market Research Report at: https://www.absolutereports.com/enquiry/request-sample/13870642   

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn’s disease or juvenile idiopathic arthritis.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion in 2017 is about 43%, and the proportion is in decreasing trend from 2013 to 2017.
USA is the largest market, with a sales market share nearly 65% in 2017. Following USA, Europe is the second largest market with the sales market share of 30%.

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim, …

Humira Market by Types

  • Humira Syringe
  • Humira Pen

    Humira Market by Applications

  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other

    Inquire More and Share Questions If Any Before the Purchase on This Report At: https://www.absolutereports.com/enquiry/pre-order-enquiry/13870642    

    This report also splits the market by region:

    Americas- United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey, GCC Countries

    Detailed TOC of Global Humira Market Growth 2019-2024

    1 Scope of the Report

    1.1 Market Introduction

    1.2 Research Objectives

    1.3 Years Considered

    1.4 Market Research Methodology

    1.5 Economic Indicators

    1.6 Currency Considered

    2 Executive Summary

    2.1 World Market Overview

    2.2 Humira Segment by Type

    2.3 Humira Consumption by Type

    2.4 Humira Segment by Application

    2.5 Humira Consumption by Application

    3 Global Humira by Players

    3.1 Global Humira Sales Market Share by Players

    3.2 Global Humira Revenue Market Share by Players

    3.4 Global Humira Manufacturing Base Distribution, Sales Area, Product Types by Players

    3.5 Market Concentration Rate Analysis

    4 Humira by Regions

    4.1 Humira by Regions

    4.2 Americas Humira Consumption Growth

    4.3 APAC Humira Consumption Growth

    4.4 Europe Humira Consumption Growth

    4.5 Middle East & Africa Humira Consumption Growth

    9 Market Drivers, Challenges and Trends

    9.1 Market Drivers and Impact

    9.2 Market Challenges and Impact

    9.3 Market Trends

    10 Marketing, Distributors and Customer

    10.1 Sales Channel

    10.1.1 Direct Channels

    10.1.2 Indirect Channels

    10.2 Humira Distributors

    10.3 Humira Customer

    11 Global Humira Market Forecast

    11.1 Global Humira Consumption Forecast (2019-2024)

    11.2 Global Humira Forecast by Regions

    11.3 Americas Forecast by Countries

    11.4 APAC Forecast by Countries

    11.5 Europe Forecast by Countries

    11.6 Middle East & Africa Forecast by Countries

    11.7 Global Humira Forecast by Type

    11.8 Global Humira Forecast by Application

    12 Key Players Analysis

    12.1 Company Details

    12.2 Humira Product Offered

    12.3 Humira Sales, Revenue, Price and Gross Margin (2019-2024)

    12.4 Main Business Overview

    13 Research Findings and Conclusion

    No. of pages: 135

    Price of Report: $ 3660 (Single User Licence) Purchase Balsa Wood Market Report at https://www.absolutereports.com/purchase/13870642    

    Browse Full Report Here: –

    https://www.absolutereports.com/global-humira-market-growth-2019-2024-13870642          

    About Absolute Reports:

    Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

    Contact Info:

    Name: Ajay More

    Email: [email protected]   

    Organization: Absolute Reports

    Phone: +14242530807/+44203239 8187

    For Other report : Global Coal Tar Pitch Binders Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2023

  • Source link

    Growth Study by Type, Application and Manufacturers Upcoming Estimates till 2024 – El Monte Daily

    Hidradenitis Suppurativa Treatment

    “Hidradenitis Suppurativa Treatment Market Analysis, Development and Forecast 2019 – 2024” providing significant insights and providing a competitive advantage to clients through a detailed report. The Hidradenitis Suppurativa Treatment Market is the basis of the development edges and scenarios, as the development of an explicit strategy needs several creatively maintained theory and methodologies. The report contains exhibit on existing market analysis development, upcoming as well as future prospects, revenue evolution, pricing and profitability.

    Ask Sample PDF of Hidradenitis Suppurativa Treatment Market Report: https://www.absolutereports.com/enquiry/request-sample/13367336 

    Hidradenitis suppurativa is a rare, inflammatory skin condition that begins as small and painful pimples on the skin. This medical condition is most common between the ages of 20-40 years. Prevalence of hidradenitis suppurativa is three times more common in females than in males..

    The worldwide market for Hidradenitis Suppurativa Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.

    Hidradenitis Suppurativa Treatment Market Segment by Manufacturers, this report covers:

    GlaxoSmithKline, , Johnson & Johnson, , Merck, , Pfizer, , AbbVie, , Allergan, , AstraZeneca, and many more.

    Hidradenitis Suppurativa Treatment Market Segment by Regions, regional analysis covers: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

    Hidradenitis Suppurativa Treatment Market Segment by Type:
    Medications
    Surgery
    Others

    Market Segment by Applications:
    Hospitals
    Clinics
    Others
    .

    Ask for Discount: https://www.absolutereports.com/enquiry/request-discount/13367336

    Key highlights considered in Hidradenitis Suppurativa Treatment market report:

    Business Expansion: A detailed Hidradenitis Suppurativa Treatment Industry information offerings a global study, modern developments, and investments.

    Business Diffusion: All topmost Hidradenitis Suppurativa Treatment Dealers, their product portfolio, market segment, and other details are presented.

    Hidradenitis Suppurativa Treatment Market Trends: supply chain analysis, Consumer analysis, import-export development, consumption, and manufacture is explained in this report.

    Latest developments and Strategies: comprehensive information on new product launch events, progress opportunities, investment feasibility, Hidradenitis Suppurativa Treatment market development factors is provided.

    Expected  Hidradenitis Suppurativa Treatment Industry Evolution: Vital details on developing  Hidradenitis Suppurativa Treatment industry segments, new players, and estimated growth during the forecast period is covered in this report.

    Complete Evaluation: Complete examination of Hidradenitis Suppurativa Treatment market plans and policies, modern development patterns and demand, and cost structures.

    Important Questions Answered in This Report:

    1.What will the Hidradenitis Suppurativa Treatment market size be by the end of the forecast period and what will the development rate be?

    2.What are the key industry trends?

    3.What are the driving factors of this Hidradenitis Suppurativa Treatment market?

    4.What are the challenges to market development?

    5.Who are the key companies in this market?

    6.What are the Hidradenitis Suppurativa Treatment market opportunities and threats faced by the foremost players?

    7.What are the strengths and weaknesses of the key players?

    Price of Report: $ 3480 (Single User License)

    Purchase Report at: https://www.absolutereports.com/purchase/13367336  

    About Absolute Reports:

    Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

    Contact Info:

    Name: Ajay More

    Email: [email protected]

    Organization: Absolute Reports

    Phone: +44 20 3239 8187/+14242530807

    Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Research Report: https://www.absolutereports.com/global-hidradenitis-suppurativa-treatment-market-2018-by-manufacturers-countries-type-and-application-forecast-to-2023-13367336

    Our latest Report: Surgical Hat Market 2019 Global Size, Growth Insight, Share, Trends, Industry Key Players, Regional Forecast to 2024

    Our latest Report: Frozen Fish Market 2019 |Global Industry Analysis by Trends, Size, Share, Company Overview, Growth and Forecast by 2024 | Latest Research Report by Absolute Reports

    Source link

    Contrasting Inflarx (IFRX) & Corvus Pharmaceuticals (NASDAQ:CRVS)

    Corvus Pharmaceuticals (NASDAQ:CRVS) and Inflarx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

    Valuation and Earnings

    This table compares Corvus Pharmaceuticals and Inflarx’s revenue, earnings per share (EPS) and valuation.

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
    Corvus Pharmaceuticals N/A N/A -$46.94 million N/A N/A
    Inflarx N/A N/A -$35.21 million ($1.40) -29.56

    Profitability

    This table compares Corvus Pharmaceuticals and Inflarx’s net margins, return on equity and return on assets.

    Net Margins Return on Equity Return on Assets
    Corvus Pharmaceuticals N/A -37.26% -34.65%
    Inflarx N/A -20.30% -19.57%

    Volatility and Risk

    Corvus Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Inflarx has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500.

    Analyst Ratings

    This is a breakdown of recent recommendations for Corvus Pharmaceuticals and Inflarx, as reported by MarketBeat.

    Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
    Corvus Pharmaceuticals 0 0 4 0 3.00
    Inflarx 0 0 7 1 3.13

    Corvus Pharmaceuticals currently has a consensus target price of $14.33, indicating a potential upside of 232.56%. Inflarx has a consensus target price of $55.00, indicating a potential upside of 32.88%. Given Corvus Pharmaceuticals’ higher possible upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Inflarx.

    Institutional and Insider Ownership

    85.8% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.0% of Inflarx shares are owned by institutional investors. 39.5% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

    Summary

    Inflarx beats Corvus Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

    Corvus Pharmaceuticals Company Profile

    Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

    Inflarx Company Profile

    InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.



    Receive News & Ratings for Corvus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

    Source link

    Pulte Group (PHM) Holder Wilsey Asset Management Raised Stake; Carmignac Gestion Has Trimmed Chemocentryx (CCXI) Stake by $769,810; Market Value Rose

    ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

    Wilsey Asset Management Inc increased its stake in Pulte Group Inc (PHM) by 2.53% based on its latest 2018Q4 regulatory filing with the SEC. Wilsey Asset Management Inc bought 12,066 shares as the company’s stock rose 3.52% with the market. The institutional investor held 489,509 shares of the capital goods company at the end of 2018Q4, valued at $12.65 million, up from 477,443 at the end of the previous reported quarter. Wilsey Asset Management Inc who had been investing in Pulte Group Inc for a number of months, seems to be bullish on the $8.90 billion market cap company. The stock increased 0.17% or $0.06 during the last trading session, reaching $32.12. About 1.04M shares traded. PulteGroup, Inc. (NYSE:PHM) has declined 3.62% since May 15, 2018 and is downtrending. It has underperformed by 7.99% the S&P500. Some Historical PHM News: 17/04/2018 – PulteGroup’s Built to Honor Program Presented with Hearthstone Donation; 04/04/2018 – PulteGroup Closes Above 50-Day Moving Average: Technicals; 07/03/2018 – PulteGroup Announces Passing of Company Founder William “Bill” Pulte; 19/04/2018 – DJ PulteGroup Inc, Inst Holders, 1Q 2018 (PHM); 25/04/2018 – PULTEGROUP INC PHM.N : CITIGROUP RAISES TARGET PRICE TO $27 FROM $25; 24/04/2018 – PULTEGROUP INC – QTRLY TOTAL REVENUES $1.97 BLN VS $1.63 BLN REPORTED LAST YEAR; 07/03/2018 – BILL PULTE, WILLIAM PULTE’S GRANDSON – “ALL PULTE FAMILY INTERESTS TO REMAIN 100% PULTE-FAMILY CONTROLLED”; 24/04/2018 – PULTEGROUP 1Q EPS 59C; 08/03/2018 – Atlanta’s first Smart Neighborhood™ features latest smart-home technologies; 15/03/2018 – PulteGroup Promotes Michelle Hairston to Senior Vice Pres, Human Re

    Carmignac Gestion decreased its stake in Chemocentryx Inc (CCXI) by 5.92% based on its latest 2018Q4 regulatory filing with the SEC. Carmignac Gestion sold 76,981 shares as the company’s stock rose 6.99% with the market. The institutional investor held 1.22M shares of the health care company at the end of 2018Q4, valued at $13.36M, down from 1.30M at the end of the previous reported quarter. Carmignac Gestion who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $710.51 million market cap company. The stock increased 2.51% or $0.3 during the last trading session, reaching $12.24. About 178,659 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since May 15, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA

    Since January 7, 2019, it had 0 buys, and 5 insider sales for $1.38 million activity. 6,172 shares valued at $74,079 were sold by Cappel Markus J. on Thursday, January 10. Shares for $447,092 were sold by Schall Thomas J. on Thursday, January 10.

    Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It worsened, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Natl Bank Of America De reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Franklin Incorporated holds 1.38 million shares or 0.01% of its portfolio. Swiss Bancshares holds 0% or 38,400 shares in its portfolio. Tiaa Cref Invest Ltd holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 311,491 shares. Sg Americas Securities Lc has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 17,971 shares. Moreover, Bb&T Securities Ltd has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Gsa Partners Limited Liability Partnership invested in 0.14% or 107,800 shares. Citigroup Inc reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameriprise Fincl has 264,496 shares. Proshare Lc, a Maryland-based fund reported 19,495 shares. Panagora Asset Mgmt, a Massachusetts-based fund reported 324,223 shares. Voya Inv Management Lc invested in 0% or 10,588 shares. Cadence Ltd Limited Liability Company, a Massachusetts-based fund reported 103,341 shares. Dimensional Fund Advsrs Ltd Partnership has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 632,061 shares. Paw Corporation accumulated 0.68% or 50,000 shares.

    Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.26 EPS, down 85.71% or $0.12 from last year’s $-0.14 per share. After $-0.23 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 13.04% negative EPS growth.

    More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” on March 28, 2019, also Nasdaq.com with their article: “ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates – Nasdaq” published on May 06, 2019, Globenewswire.com published: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” on May 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference – GlobeNewswire” published on February 20, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” with publication date: May 06, 2019.

    Carmignac Gestion, which manages about $6.62B US Long portfolio, upped its stake in Carrizo Oil & Gas Inc (NASDAQ:CRZO) by 47,410 shares to 695,599 shares, valued at $7.85M in 2018Q4, according to the filing. It also increased its holding in Facebook Inc (NASDAQ:FB) by 82,138 shares in the quarter, for a total of 2.78M shares, and has risen its stake in Grubhub Inc (NYSE:GRUB).

    More notable recent PulteGroup, Inc. (NYSE:PHM) news were published by: 247Wallst.com which released: “Top Analyst Upgrades and Downgrades: Apple, Best Buy, Eli Lilly, Hilton, Hyatt, Kraft Heinz, Procter & Gamble, Snap and More – 24/7 Wall St.” on April 24, 2019, also Seekingalpha.com with their article: “PulteGroup Q1 2019 Earnings Preview – Seeking Alpha” published on April 22, 2019, Fool.com published: “PulteGroup’s Management Changes Its Tune on the Housing Market – The Motley Fool” on April 28, 2019. More interesting news about PulteGroup, Inc. (NYSE:PHM) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For April 24, 2019 – Benzinga” published on April 24, 2019 as well as Finance.Yahoo.com‘s news article titled: “Did You Miss PulteGroup’s (NYSE:PHM) 74% Share Price Gain? – Yahoo Finance” with publication date: May 06, 2019.

    Investors sentiment decreased to 0.8 in 2018 Q4. Its down 0.15, from 0.95 in 2018Q3. It dived, as 56 investors sold PHM shares while 164 reduced holdings. 63 funds opened positions while 113 raised stakes. 233.24 million shares or 2.77% less from 239.88 million shares in 2018Q3 were reported. Twin Management has invested 0.41% in PulteGroup, Inc. (NYSE:PHM). Manufacturers Life Ins The owns 229,039 shares. Hellman Jordan Ma reported 42,982 shares. Acadian Asset Mgmt Ltd invested in 0% or 8,947 shares. Mckinley Carter Wealth Svcs invested 0.09% in PulteGroup, Inc. (NYSE:PHM). Exane Derivatives accumulated 0% or 501 shares. Neuberger Berman Grp Llc holds 0% or 8,861 shares. Piedmont Invest holds 9,769 shares or 0.01% of its portfolio. Cwm Ltd Liability Co accumulated 20 shares or 0% of the stock. North Carolina-based Salem Invest Counselors Inc has invested 0.04% in PulteGroup, Inc. (NYSE:PHM). Meiji Yasuda Asset Management invested 0.05% in PulteGroup, Inc. (NYSE:PHM). Alps Advisors Inc stated it has 16,799 shares or 0% of all its holdings. Asset Mgmt One Limited accumulated 0.03% or 435,453 shares. Peloton Wealth Strategists accumulated 89,300 shares or 1.89% of the stock. Pggm Invests has invested 0.17% in PulteGroup, Inc. (NYSE:PHM).

    PulteGroup, Inc. (NYSE:PHM) Institutional Positions Chart

    Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

    Source link

    Carmignac Gestion Cut Its Stake in Chemocentryx (CCXI) by $769,810; United Services Automobile Association Decreased Its Stake in Expeditors International Of Washington (EXPD) by $6.48 Million as Share Value Declined

    Expeditors International of Washington, Inc. (NASDAQ:EXPD) Logo

    Carmignac Gestion decreased its stake in Chemocentryx Inc (CCXI) by 5.92% based on its latest 2018Q4 regulatory filing with the SEC. Carmignac Gestion sold 76,981 shares as the company’s stock rose 6.99% with the market. The institutional investor held 1.22M shares of the health care company at the end of 2018Q4, valued at $13.36M, down from 1.30 million at the end of the previous reported quarter. Carmignac Gestion who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $708.44 million market cap company. The stock increased 2.21% or $0.26 during the last trading session, reaching $12.2. About 155,427 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since May 15, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in

    United Services Automobile Association decreased its stake in Expeditors International Of Washington Inc (EXPD) by 11.1% based on its latest 2018Q4 regulatory filing with the SEC. United Services Automobile Association sold 95,252 shares as the company’s stock declined 1.99% while stock markets rallied. The institutional investor held 763,078 shares of the transportation company at the end of 2018Q4, valued at $51.96M, down from 858,330 at the end of the previous reported quarter. United Services Automobile Association who had been investing in Expeditors International Of Washington Inc for a number of months, seems to be less bullish one the $12.64 billion market cap company. The stock increased 0.93% or $0.68 during the last trading session, reaching $73.51. About 333,404 shares traded. Expeditors International of Washington, Inc. (NASDAQ:EXPD) has risen 19.55% since May 15, 2018 and is uptrending. It has outperformed by 15.18% the S&P500. Some Historical EXPD News: 22/05/2018 – EXPEDITORS INTERNATIONAL OF WASHINGTON SAYS SHIPPERS WILL NEED TO REFINE THEIR FUTURE ORDER PROJECTIONS TO ALLEVIATE SOME OF CONSTRAINTS – SEC FILING; 08/05/2018 – EXPEDITORS 1Q EPS 76C, EST. 65C; 08/05/2018 – Expeditors International 1Q Rev $1.85B; 09/05/2018 – EXPEDITORS INTERNATIONAL OF WASHINGTON INC EXPD.O : BARCLAYS RAISES TARGET PRICE TO $78 FROM $70; 08/05/2018 – Expeditors Reports First Quarter 2018 EPS of $0.76; 08/05/2018 – Expeditors International 1Q EPS 76c; 08/05/2018 – EXPEDITORS 1Q REV. $1.9B, EST. $1.71B; 07/05/2018 – Pacific Expeditors Named Company Of The Year By The 2018 American Business Awards®; 09/05/2018 – Expeditors Announces Semi-Annual Cash Dividend of $0.45; 22/05/2018 – EXPEDITORS INTERNATIONAL OF WASHINGTON – MOMENTUM OF GLOBAL TRADE GROWTH IN 2017 APPEARS TO BE CONTINUING IN EARLY 2018 IN A SIMILAR MANNER

    Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.26 EPS, down 85.71% or $0.12 from last year’s $-0.14 per share. After $-0.23 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 13.04% negative EPS growth.

    Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It fall, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Matarin Ltd Company reported 81,534 shares. The Massachusetts-based Panagora Asset Mgmt has invested 0.02% in ChemoCentryx, Inc. (NASDAQ:CCXI). Moreover, Sei Invests has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 69,428 shares. Franklin Resource invested in 1.38M shares or 0.01% of the stock. Financial Bank Of New York Mellon has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Strs Ohio reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Wasatch Advsr Inc stated it has 2.32 million shares or 0.34% of all its holdings. Morgan Stanley invested in 0% or 39,571 shares. Prelude Capital Management Ltd Liability owns 1,076 shares. Aqr Mngmt Ltd Liability Com holds 22,364 shares or 0% of its portfolio. Fmr Ltd Liability Co invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameritas Prtn Incorporated reported 2,120 shares. State Of Wisconsin Inv Board reported 23,200 shares stake. Smith Asset Mgmt Gru Limited Partnership accumulated 22,897 shares or 0.01% of the stock. Swiss Bank holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 38,400 shares.

    Carmignac Gestion, which manages about $6.62B US Long portfolio, upped its stake in Grubhub Inc (NYSE:GRUB) by 1.13M shares to 2.40 million shares, valued at $184.38 million in 2018Q4, according to the filing. It also increased its holding in Cl A by 40,714 shares in the quarter, for a total of 333,982 shares, and has risen its stake in Anthem Inc (NYSE:ANTM).

    More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “Report: Exploring Fundamental Drivers Behind Lincoln National, News Corporation, Macerich, ChemoCentryx, Delek Logistics Partners, and SunCoke Energy Partners — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” on April 16, 2019, also Seekingalpha.com with their article: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” published on May 06, 2019, Seekingalpha.com published: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” on September 28, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” published on May 06, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: March 12, 2019.

    Since January 7, 2019, it had 0 insider purchases, and 5 sales for $1.38 million activity. $74,079 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares were sold by Cappel Markus J.. KANAYA SUSAN M sold $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, January 22.

    More notable recent Expeditors International of Washington, Inc. (NASDAQ:EXPD) news were published by: Nasdaq.com which released: “First Week of EXPD April 18th Options Trading – Nasdaq” on April 10, 2019, also Nasdaq.com with their article: “Genesee & Wyoming (GWR) Misses on Q1 Earnings & Revenues – Nasdaq” published on May 02, 2019, Nasdaq.com published: “Old Dominion (ODFL) Q1 Earnings Top Estimates, Rise Y/Y – Nasdaq” on April 30, 2019. More interesting news about Expeditors International of Washington, Inc. (NASDAQ:EXPD) were released by: Nasdaq.com and their article: “Expeditors International (EXPD) Misses Q1 Earnings Estimates – Nasdaq” published on May 07, 2019 as well as Finance.Yahoo.com‘s news article titled: “Will Expeditors International of Washington, Inc.’s (NASDAQ:EXPD) Earnings Grow In The Next 12 Months? – Yahoo Finance” with publication date: April 25, 2019.

    Investors sentiment increased to 1 in 2018 Q4. Its up 0.02, from 0.98 in 2018Q3. It is positive, as 46 investors sold EXPD shares while 158 reduced holdings. 51 funds opened positions while 153 raised stakes. 157.56 million shares or 1.49% more from 155.26 million shares in 2018Q3 were reported. State Of Alaska Department Of Revenue has 42,550 shares. Laurion Capital LP owns 4,962 shares. Rwc Asset Llp stated it has 1.16% in Expeditors International of Washington, Inc. (NASDAQ:EXPD). 959,306 are owned by Swiss Bankshares. Ubs Asset Americas holds 1.61 million shares. 67 were accumulated by Benjamin F Edwards &. Amica Mutual Insur accumulated 6,899 shares. Richard Bernstein Advisors Ltd Liability owns 0.11% invested in Expeditors International of Washington, Inc. (NASDAQ:EXPD) for 43,363 shares. Moreover, Hl Limited Liability Corp has 1.37% invested in Expeditors International of Washington, Inc. (NASDAQ:EXPD) for 1.15M shares. First Interstate Commercial Bank invested 0.13% in Expeditors International of Washington, Inc. (NASDAQ:EXPD). Intl holds 0.02% or 71,550 shares. Arcadia Invest Management Corp Mi holds 0.12% in Expeditors International of Washington, Inc. (NASDAQ:EXPD) or 5,373 shares. Gateway Inv Advisers Ltd Com has invested 0% in Expeditors International of Washington, Inc. (NASDAQ:EXPD). Balyasny Asset Ltd Liability reported 22,674 shares stake. Cwm Ltd Liability Corp accumulated 2,320 shares or 0% of the stock.

    United Services Automobile Association, which manages about $34.48 billion US Long portfolio, upped its stake in Ring Energy Inc (NYSEMKT:REI) by 87,547 shares to 344,785 shares, valued at $1.75 million in 2018Q4, according to the filing. It also increased its holding in Fortinet Inc (NASDAQ:FTNT) by 34,562 shares in the quarter, for a total of 117,712 shares, and has risen its stake in Church & Dwight Co Inc (NYSE:CHD).

    Since November 16, 2018, it had 0 insider purchases, and 2 selling transactions for $2.65 million activity. Musser Jeffrey S sold $2.28 million worth of stock. Emmert Mark A sold $367,600 worth of stock.

    Expeditors International of Washington, Inc. (NASDAQ:EXPD) Institutional Positions Chart

    Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

    Source link

    Contrasting of Avid Bioservices Inc. (CDMOP) and InflaRx N.V. (NASDAQ:IFRX)

    Avid Bioservices Inc. (NASDAQ:CDMOP) and InflaRx N.V. (NASDAQ:IFRX) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

    Earnings & Valuation

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
    Avid Bioservices Inc. 43.49M 4.75 16.11M -0.31 0.00
    InflaRx N.V. N/A 0.00 N/A -1.42 0.00

    Demonstrates Avid Bioservices Inc. and InflaRx N.V. earnings per share, gross revenue and valuation.

    Profitability

    Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

    Net Margins Return on Equity Return on Assets
    Avid Bioservices Inc. -37.04% 0% 0%
    InflaRx N.V. 0.00% -22.7% -21.9%

    Analyst Recommendations

    The next table highlights the shown recommendations and ratings for Avid Bioservices Inc. and InflaRx N.V.

    Sell Ratings Hold Ratings Buy Ratings Rating Score
    Avid Bioservices Inc. 0 0 0 0.00
    InflaRx N.V. 0 0 1 3.00

    Competitively the consensus price target of InflaRx N.V. is $58, which is potential 40.13% upside.

    Institutional and Insider Ownership

    Avid Bioservices Inc. and InflaRx N.V. has shares owned by institutional investors as follows: 0.72% and 58.4%. Avid Bioservices Inc.’s share owned by insiders are 7.06%.

    Performance

    In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

    Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
    Avid Bioservices Inc. 0.85% 1.09% 8.25% 1.61% 6.87% 3.88%
    InflaRx N.V. 16.4% 16.44% 25.22% 14.31% 39.39% 4.98%

    For the past year Avid Bioservices Inc.’s stock price has smaller growth than InflaRx N.V.

    InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.

    Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

    Source link